BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Senior's Manual for Obtaining a Hyundai Ioniq EV: Tips- South Carolina measles outbreak grows by nearly 100, spreads to North Carolina and Ohio
- 5 Different ways Macintosh is Prepared to Overwhelm Gaming, Even Against Windows
- How did I get my own unique set of fingerprints?
- Can ICE agents detain U.S. citizens? What powers do they have to arrest people? Your most common questions answered.
- 'Inflaming tensions': Bedouin mayor slams Ben-Gvir's unauthorized visit after meeting cancellation
- Higher cost, worse coverage: Affordable Care Act enrollees say expiring subsidies will hit them hard
- Manual for Picking the Ideal Wine Matching
- Interoceanic Train derails in southern Mexico, injuring at least 15 and halting traffic on line
